Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structural and functional comparison of SARS-CoV-2-spike receptor binding domain produced in Pichia pastoris and mammalian cells

11 Dec 2020

Abstract excerpt

Abstract The yeast Pichia pastoris is a cost-effective and easily scalable system for recombinant protein production. In this work we compared the conformation of the receptor binding domain (RBD) from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Spike protein expressed in P. pastoris and in the well established HEK-293T mammalian cell system. RBD obtained from both yeast and mammalian cells was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacillus and Francisella bacterial research
Share to Computational Drug Discovery Methods
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33311634
DOI: 10.1038/s41598-020-78711-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structural and functional comparison of SARS-CoV-2-spike receptor binding domain produced in Pichia pastoris and mammalian cellsPMID 33311634Read ↗

The Nuts and Bolts of SARS-CoV-2 Spike Receptor-Binding Domain Heterologous ExpressionSemantic proximity Read ↗

Scale-up Production and Immunological Assessment of Recombinant SARS- CoV-2 Spike RBD in Pichia pastorisSemantic proximity Read ↗

Scalable Production of a <i>De Novo</i> SARS-CoV-2 Antiviral miniprotein in E <i>scherichia coli</i>Semantic proximity Read ↗

Purification and characterization of the receptor‐binding domain of SARS‐CoV‐2 spike protein from Escherichia coliSemantic proximity Read ↗

A Vaccine Based on the Receptor-Binding Domain of the Spike Protein Expressed in Glycoengineered Pichia pastoris Targeting SARS-CoV-2 Stimulates Neutralizing and Protective Antibody ResponsesSemantic proximity Read ↗

Genetic Modification to Design a Stable Yeast-expressed Recombinant SARS-CoV-2 Receptor Binding Domain as a COVID-19 Vaccine CandidateSemantic proximity Read ↗

Yeast-expressed Recombinant SARS-CoV-2 Receptor Binding Domain, RBD203-N1 as a COVID-19 Protein Vaccine CandidateSemantic proximity Read ↗

Scalable, methanol-free manufacturing of the SARS-CoV-2 receptor binding domain in engineered <i>Komagataella phaffii</i>Semantic proximity Read ↗

Expression, purification and characterization of SARS-CoV-2 spike RBD in ExpiCHO cellsSemantic proximity Read ↗

Design, expression, purification and characterization of a YFP-tagged 2019-nCoV spike receptor-binding domain constructSemantic proximity Read ↗

Enhanced Expression and Solubility of Main Protease (Mpro) of SARS-CoV-2 from E. ColiSemantic proximity Read ↗

A recombinant Lactobacillus plantarum strain expressing the spike protein of SARS-CoV-2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.